Biocryst Pharmaceuticals(BCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BCRX Biocryst Pharmaceuticals

Market Closed 12-12 16:00:00 EST

7.57

-0.01

-0.13%

盘后7.56

-0.01-0.13%

19:53 EST

High7.82	Low7.23	Vol5.22M
Open7.82	D1 Closing7.58	Amplitude7.78%
Mkt Cap1.59B	Tradable Cap1.57B	Total Shares210.54M
T/O39.41M	T/O Rate2.51%	Tradable Shares207.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BCRX","market":"US","secType":"STK","nameCN":"Biocryst Pharmaceuticals","latestPrice":7.57,"timestamp":1765573200000,"preClose":7.58,"halted":0,"volume":5223129,"hourTrading":{"tag":"盘后","latestPrice":7.56,"preClose":7.57,"latestTime":"19:53 EST","volume":142373,"amount":1076901.8884,"timestamp":1765587234336},"delay":0,"floatShares":207688912,"shares":210543224,"eps":-0.045319,"marketStatus":"Market Closed","change":-0.01,"latestTime":"12-12 16:00:00 EST","open":7.82,"high":7.82,"low":7.23,"amount":39410949.5954946,"amplitude":0.077836,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.045319,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":762670800000,"exchange":"NASDAQ","adjPreClose":7.58,"preHourTrading":{"tag":"盘前","latestPrice":7.86,"preClose":7.58,"latestTime":"09:29 EST","volume":290098,"amount":2311835.346994,"timestamp":1765549765263},"postHourTrading":{"tag":"盘后","latestPrice":7.56,"preClose":7.57,"latestTime":"19:53 EST","volume":142373,"amount":1076901.8884,"timestamp":1765587234336},"volumeRatio":1.6709306641043604,"impliedVol":0.61,"impliedVolPercentile":0.812},"requestUrl":"/m/hq/s/BCRX","defaultTab":"news","newsList":[{"id":"2590250290","title":"BioCryst Pharmaceuticals Shares Reverse Premarket Course, Last Down 1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590250290","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590250290?lang=en_us&edition=fundamental","pubTime":"2025-12-12 22:39","pubTimestamp":1765550341,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nL4N3XI11T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4547","BCRX","BK4139"],"gpt_icon":0},{"id":"2590047895","title":"Sector Update: Health Care Stocks Edge Higher Premarket Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2590047895","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590047895?lang=en_us&edition=fundamental","pubTime":"2025-12-12 22:18","pubTimestamp":1765549108,"startTime":"0","endTime":"0","summary":"Health care stocks were edging higher premarket Friday, with the State Street Health Care Select Sector SPDR ETF  advancing by 0.6% and the iShares Biotechnology ETF  up 0.1%.Relay Therapeutics  shares were up more than 11% after the company said interim results from a study of zovegalisib plus fulvestrant to treat breast cancer patients showed \"robust activity.\"ImmunityBio  stock was up more than 4% after the company said the European Medicines Agency has recommended granting a conditional marketing authorization for anktiva in combination with BCG for the treatment of BGC-unresponsive non-muscle invasive bladder cancer.BioCryst Pharmaceuticals  shares were up more than 2% after the company said the US Food and Drug Administration approved Orladeyo oral pellets to help prevent hereditary angioedema attacks in children ages 2 to under 12.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4563","BK4581","IBRX","BCRX","BK4139","RLAY","BK4547","BK4588","LABU","XLV","IBB","BK4585","XBI"],"gpt_icon":0},{"id":"2590878504","title":"Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Friday as Broadcom Results Deepen Fears","url":"https://stock-news.laohu8.com/highlight/detail?id=2590878504","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590878504?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:55","pubTimestamp":1765547734,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1% and the actively traded Invesco QQQ Trust (QQQ) was 0.5% lower in Friday's premarket activity as Broadcom's (AVGO) quar","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f7a0f8aa044e4562b606d0f447f56531","theme_name":"🔥TrendingNo.2 · Broadcom Earnings Impact and AI Market Sentiment Affecting US Stock Futures and S&P 500 Record High","theme_type":2,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RTH.AU","VHT.AU","BCRX","XLI","SOXX","EETH","XSD","TE","BETH","XRT","XLV","RTH","EEM","SPY.AU","VHT","XLP","VDC","IYW","IPK","FAS","SPY","IYH","EQR","XLK","IVV","PMR","IGM","NX",".DJI","VIS","USO","FAZ","IBB",".IXIC","IYK","XLF","UNG","XLY","AVGO","XLE","IGV","EXI","BITO","IYE","IYJ"],"gpt_icon":1},{"id":"2590506548","title":"BioCryst Pharmaceuticals Shares up 2.9% Premarket After FDA Nod of Rare Disease Drug for Children","url":"https://stock-news.laohu8.com/highlight/detail?id=2590506548","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590506548?lang=en_us&edition=fundamental","pubTime":"2025-12-12 20:30","pubTimestamp":1765542606,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nFWN3XI0PE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4547","BCRX","BK4139"],"gpt_icon":0},{"id":"2590250597","title":"FDA expands approval of BioCryst's rare disease drug for use in young children","url":"https://stock-news.laohu8.com/highlight/detail?id=2590250597","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590250597?lang=en_us&edition=fundamental","pubTime":"2025-12-12 20:05","pubTimestamp":1765541110,"startTime":"0","endTime":"0","summary":"FDA expands approval of BioCryst's rare disease drug for use in young childrenDec 12  - The U.S. Food and Drug Administration has expanded the use of BioCryst Pharmaceuticals' BCRX.O drug to include an oral pellet formulation for preventing hereditary angioedema attacks in children aged 2 to under 12 years, the company said on Friday.  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nL4N3XI0UI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4139","BCRX"],"gpt_icon":0},{"id":"2590950568","title":"FDA Approves BioCryst's ORLADEYO Oral Pellets for Pediatric HAE Prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=2590950568","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590950568?lang=en_us&edition=fundamental","pubTime":"2025-12-12 20:00","pubTimestamp":1765540828,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration  has approved its New Drug Application  for an oral pellet formulation of ORLADEYO  for prophylactic therapy in pediatric patients with hereditary angioedema  aged 2 to less than 12 years. This approval makes ORLADEYO the first and only targeted oral prophylactic therapy available for patients with HAE aged 2 and older. The new oral pellet formulation is designed to provide a child-friendly method of administration and demonstrated early and sustained reductions in monthly attack rates in clinical studies. BioCryst has also filed applications for the use of ORLADEYO oral pellets in children with HAE in Europe and Japan, with additional regulatory filings planned in other global territories, including Canada.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL2d09S5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4585","SG9999014005.SGD","BCRX","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","NDAQ","SG9999014021.USD","BK4588","BK4139","SG9999014039.USD","LU2210149790.SGD","LU2095319765.USD","LU0314104364.USD","IE00BGHQF748.EUR","SG9999014013.SGD","LU2210150020.SGD","BK4547","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2590505347","title":"BioCryst Announces FDA Approval of Orladeyo® (Berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients With Hae Aged 2 to <12 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2590505347","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590505347?lang=en_us&edition=fundamental","pubTime":"2025-12-12 20:00","pubTimestamp":1765540800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nTUA3MBYJQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4547","BCRX","BK4139"],"gpt_icon":0},{"id":"2590503466","title":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 06:41 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2590503466","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590503466?lang=en_us&edition=fundamental","pubTime":"2025-12-12 19:41","pubTimestamp":1765539702,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 06:41 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nAQN2LDCFZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4547","BCRX"],"gpt_icon":0},{"id":"2590414513","title":"BioCryst Pharmaceuticals Inc - on Dec 9, Vincent J. Milano Elected as Next Chair of Board - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2590414513","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590414513?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:28","pubTimestamp":1765456124,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nFWN3XH0L0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCRX","BK4139","BK4547"],"gpt_icon":0},{"id":"2590513416","title":"Vincent J. Milano Named Next Chair of BioCryst Pharmaceuticals Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2590513416","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590513416?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:26","pubTimestamp":1765455990,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals Inc. announced that Nancy J. Hutson, Ph.D. will retire from the Board of Directors, effective either upon the closing of the proposed acquisition of Astria Therapeutics, Inc. or at the company's 2026 annual meeting of stockholders, whichever comes first. Vincent J. Milano has been elected as the next Chair of the Board, to assume the role upon Dr. Hutson's retirement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 11, 2025, and is solely responsible for the information contained","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL7r4N4N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCRX","ATXS","BK4139","BK4547"],"gpt_icon":0},{"id":"2588288968","title":"BioCryst Grants New Hires Stock Options and RSUs as Inducement","url":"https://stock-news.laohu8.com/highlight/detail?id=2588288968","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588288968?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:00","pubTimestamp":1764849625,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals Inc. has granted stock options to purchase a total of 57,100 shares and restricted stock units  covering 46,400 shares of common stock to four newly hired employees. The stock options have an exercise price of $7.13 per share, equal to the closing price on the grant date of December 1, 2025. Both the options and RSUs will vest in four equal annual installments starting on the first anniversary of the grant date, provided the employees remain with the company. Each stock option carries a 10-year term.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on December 04, 2025, and is solely responsible for th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL24SY75:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2210149790.SGD","NDAQ","BK4585","BK4139","BCRX","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4112","LU0314104364.USD","BK4547","LU2095319765.USD","LU2210150020.SGD"],"gpt_icon":0},{"id":"2588200710","title":"BioCryst Chief Legal Officer Alane P. Barnes Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588200710","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588200710?lang=en_us&edition=fundamental","pubTime":"2025-12-04 07:41","pubTimestamp":1764805283,"startTime":"0","endTime":"0","summary":"Alane P. Barnes, Chief Legal Officer of BioCryst Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 03, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL1kBtHd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BioCryst Chief Legal Officer Alane P. Barnes Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4139","BCRX"],"gpt_icon":0},{"id":"2588367049","title":"BRIEF-Biocryst Receives Early Termination Of Hart-Scott-Rodino Waiting Period For Astria Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2588367049","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588367049?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:05","pubTimestamp":1764767146,"startTime":"0","endTime":"0","summary":"BRIEF-Biocryst Receives Early Termination Of Hart-Scott-Rodino Waiting Period For Astria AcquisitionDec 3 (Reuters) - BioCryst Pharmaceuticals Inc BCRX.O:BIOCRYST RECEIVES EARLY TERMINATION OF HART-SC","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nTUA6BK0ZH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BCRX","BK4139"],"gpt_icon":0},{"id":"2588046804","title":"BioCryst Pharmaceuticals-Astria Deal Clears Regulatory Hurdle","url":"https://stock-news.laohu8.com/highlight/detail?id=2588046804","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588046804?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:42","pubTimestamp":1764765750,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals  said Wednesday it received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act with respect to the company's proposed acquisition of Astria Therapeutics.The termination satisfied one of the conditions for the deal's completion, expected in Q1, the company said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCRX","BK4139","BK4547"],"gpt_icon":0},{"id":"2588043423","title":"BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2588043423","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588043423?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:00","pubTimestamp":1764763213,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals disclosed plans to merge with Astria Therapeutics. The announcement highlights expectations regarding the timing of the closing and potential benefits, including anticipated synergies from the combined operations. However, BioCryst noted there are risks and uncertainties that could affect the completion and outcome of the merger. The companies also referenced the possibility of integration challenges, potential expenses, and impacts on business relationships as factors that could influence the transaction. Further details are available in filings with the SEC.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNew","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDLVYpBk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4588","BK4547","BK4139","LU2095319765.USD","BK4112","LU0314104364.USD","BCRX","LU2210150020.SGD","IE00B3QW5Z07.USD","ATXS","NDAQ","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2210149790.SGD","BK4585"],"gpt_icon":0},{"id":"2588043217","title":"BioCryst Pharmaceuticals Inc - Expects Merger to Close in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2588043217","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588043217?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:00","pubTimestamp":1764763201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nTUA6BK0ZH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCRX","BK4547"],"gpt_icon":0},{"id":"2588525530","title":"How New Pediatric APeX-P Data at BioCryst (BCRX) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2588525530","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588525530?lang=en_us&edition=fundamental","pubTime":"2025-12-02 22:14","pubTimestamp":1764684852,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals recently announced new one-year data from its APeX-P trial, highlighting that ORLADEYO (berotralstat) treatment led to early and sustained reductions in hereditary angioedema (HAE) attack rates in children aged 2 to under 12 years.\nThe results also underscored the significant psychosocial impact of HAE on pediatric patients and their caregivers, further supporting the importance of effective therapies for this population.\nWe'll explore how these clinical findings in...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/how-new-pediatric-apex-p-data-at-biocryst-bcrx-has-changed-i","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/how-new-pediatric-apex-p-data-at-biocryst-bcrx-has-changed-i","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00B19Z6F94.USD","BK4198","IE0034390439.USD","LU0205193047.USD","BK4139","LU1169590202.USD","IE00B64QTZ34.USD","BCRX","IE00BLDYK493.USD","LU0012050646.USD","LU0106261612.USD","LU1169589451.USD","HAE","BK4547","LU0205194284.USD"],"gpt_icon":0},{"id":"2584942457","title":"BioCryst (BCRX) Receives a Buy from Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2584942457","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584942457?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:55","pubTimestamp":1763560558,"startTime":"0","endTime":"0","summary":"In a report released today, Laura Chico from Wedbush maintained a Buy rating on BioCryst, with a price target of $21.00. Chico covers the Healthcar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/biocryst-bcrx-receives-a-buy-from-wedbush-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/biocryst-bcrx-receives-a-buy-from-wedbush-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4547","BCRX","BK4139"],"gpt_icon":0},{"id":"2584705961","title":"Assessing BioCryst Pharmaceuticals (BCRX) Valuation After Promising Pediatric ORLADEYO Trial Results and FDA Review Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2584705961","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584705961?lang=en_us&edition=fundamental","pubTime":"2025-11-19 03:27","pubTimestamp":1763494032,"startTime":"0","endTime":"0","summary":"BioCryst Pharmaceuticals (BCRX) released fresh data from its APeX-P trial, showing that children aged 2 to 12 treated with ORLADEYO experienced early and lasting reductions in their monthly hereditary angioedema attack rates.\nSee our latest analysis for BioCryst Pharmaceuticals.\nBioCryst Pharmaceuticals has attracted attention following its promising new pediatric trial data and the ongoing FDA review of ORLADEYO's oral granule formulation. After a volatile year, momentum looks to be...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/assessing-biocryst-pharmaceuticals-bcrx-valuation-after-prom","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcrx/biocryst-pharmaceuticals/news/assessing-biocryst-pharmaceuticals-bcrx-valuation-after-prom","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4547","BCRX"],"gpt_icon":0},{"id":"2584467177","title":"BioCryst Director Machelle Sanders Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584467177","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584467177?lang=en_us&edition=fundamental","pubTime":"2025-11-18 05:07","pubTimestamp":1763413663,"startTime":"0","endTime":"0","summary":"Machelle Sanders, Director of BioCryst Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 17, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDLb8jpVy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BioCryst Director Machelle Sanders Reports Sale of Common Shares","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCRX","BK4139","BK4547"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biocryst.com","stockEarnings":[{"period":"1week","weight":-0.0026},{"period":"1month","weight":0.0543},{"period":"3month","weight":-0.043},{"period":"6month","weight":-0.27},{"period":"1year","weight":-0.0039},{"period":"ytd","weight":0.0066}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor for complement-mediated diseases; and Galidesivir, to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.","yearOnYearQuotes":[{"month":1,"riseRate":0.580645,"avgChangeRate":0.031172},{"month":2,"riseRate":0.516129,"avgChangeRate":-0.010813},{"month":3,"riseRate":0.354839,"avgChangeRate":0.014971},{"month":4,"riseRate":0.5625,"avgChangeRate":0.048894},{"month":5,"riseRate":0.5625,"avgChangeRate":0.062945},{"month":6,"riseRate":0.59375,"avgChangeRate":0.027194},{"month":7,"riseRate":0.5625,"avgChangeRate":0.113207},{"month":8,"riseRate":0.59375,"avgChangeRate":0.099672},{"month":9,"riseRate":0.34375,"avgChangeRate":-0.049493},{"month":10,"riseRate":0.5,"avgChangeRate":-0.046955},{"month":11,"riseRate":0.46875,"avgChangeRate":0.037572},{"month":12,"riseRate":0.5,"avgChangeRate":0.003697}],"exchange":"NASDAQ","name":"Biocryst Pharmaceuticals","nameEN":"Biocryst Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biocryst Pharmaceuticals(BCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biocryst Pharmaceuticals(BCRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biocryst Pharmaceuticals,BCRX,Biocryst Pharmaceuticals股票,Biocryst Pharmaceuticals股票老虎,Biocryst Pharmaceuticals股票老虎国际,Biocryst Pharmaceuticals行情,Biocryst Pharmaceuticals股票行情,Biocryst Pharmaceuticals股价,Biocryst Pharmaceuticals股市,Biocryst Pharmaceuticals股票价格,Biocryst Pharmaceuticals股票交易,Biocryst Pharmaceuticals股票购买,Biocryst Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biocryst Pharmaceuticals(BCRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biocryst Pharmaceuticals(BCRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}